Kazia Therapeutics Limited ADR (NASDAQ:KZIA) has a beta value of 2.12 and has seen 1.37 million shares traded in the last trading session. The company, currently valued at $7.80M, closed the last trade at $0.33 per share which meant it lost -$0.07 on the day or -18.01% during that session. The KZIA stock price is -378.79% off its 52-week high price of $1.58 and 42.42% above the 52-week low of $0.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.53 million shares traded. The 3-month trading volume is 2.19 million shares.
The consensus among analysts is that Kazia Therapeutics Limited ADR (KZIA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information
Sporting -18.01% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the KZIA stock price touched $0.33 or saw a rise of 20.44%. Year-to-date, Kazia Therapeutics Limited ADR shares have moved -24.89%, while the 5-day performance has seen it change -22.51%. Over the past 30 days, the shares of Kazia Therapeutics Limited ADR (NASDAQ:KZIA) have changed -2.91%. Short interest in the company has seen 0.31 million shares shorted with days to cover at 0.2.
Kazia Therapeutics Limited ADR (KZIA) estimates and forecasts
The company’s shares have gained 13.44% over the past 6 months, compared to 17.40% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.22% over the past 5 years.
KZIA Dividends
Kazia Therapeutics Limited ADR is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s Major holders
Investors are also buoyed by the number of investors in a company, with Kazia Therapeutics Limited ADR having a total of 12.0 institutions that hold shares in the company. The top two institutional holders are MORGAN STANLEY with over 0.2 million shares worth more than $45967.0. As of 2024-06-30, MORGAN STANLEY held 0.8386% of shares outstanding.
The other major institutional holder is BNP PARIBAS ARBITRAGE, SNC, with the holding of over 63568.0 shares as of 2024-06-30. The firm’s total holdings are worth over $14532.0 and represent 0.2651% of shares outstanding.
